Actinium Pharmaceuticals, Inc. (ATNM)

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Negative EBIT growth while AGEN is at 260.67%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.

Negative operating income growth while AGEN is at 258.49%. Joel Greenblatt would press for urgent turnaround measures.

Negative net income growth while AGEN stands at 212.41%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.

Negative EPS growth while AGEN is at 207.41%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.

Negative diluted EPS growth while AGEN is at 207.41%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.

Share change of 22.83% while AGEN is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.

Diluted share change of 22.83% while AGEN is zero. Bruce Berkowitz might see a minor difference that could widen over time.

No Data available this quarter, please select a different quarter.

Negative OCF growth while AGEN is at 369.63%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.

Negative FCF growth while AGEN is at 369.63%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Negative 10Y OCF/share CAGR while AGEN stands at 122.41%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.

Negative 5Y OCF/share CAGR while AGEN is at 142.46%. Joel Greenblatt would question the firm’s operational model or cost structure.

3Y OCF/share CAGR under 50% of AGEN's 158.37%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.

Negative 10Y net income/share CAGR while AGEN is at 113.75%. Joel Greenblatt sees a major red flag in long-term profit erosion.

Negative 5Y net income/share CAGR while AGEN is 126.69%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.

Negative 3Y CAGR while AGEN is 135.64%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.

Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.

Negative 5Y equity/share growth while AGEN is at 77.93%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

Below 50% of AGEN's 73.65%. Michael Burry suspects a serious short-term disadvantage in building book value.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Firm’s AR is declining while AGEN shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.

No Data available this quarter, please select a different quarter.

Under 50% of AGEN's 48.96%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.

Debt growth far above AGEN's 1.16%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.

SG&A growth well above AGEN's 6.05%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.